Advanced Biotherapy, Inc. Announces Lecture Invitation of Dr. Simon Skurkovich and Resignation of Paul J. Marangos, Ph.D. From Board of Directors.

Business Editors

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--May 29, 2001

Advanced Biotherapy, Inc. (OTCBB:ADVB), announced today that the company's Founder, Chairman Emeritus and Vice President of Research and Development, Dr. Simon Skurkovich, has been invited to lecture and make presentations regarding the company's scientific approach, rationale, and clinical trial findings in Moscow, Russia during the week of June 4, 2001.

The invitation came as a result of the company's scientific findings in two randomized, placebo-controlled, double blind trials conducted in Russia, demonstrating efficacy of its anti-cytokine strategy, pioneered by Dr. Skurkovich, in both rheumatoid arthritis (RA) and multiple sclerosis (MS).

Dr. Skurkovich will be presenting such lectures at the Institute of Rheumatology at the Medical Academy of the Russian Federation, the Departments of Neurology and Neurosurgery at Moscow Medical University, the Institute of Eye Diseases and the Institute of Pediatrics, also at the Medical Academy of the Russian Federation. Dr. Skurkovich is also being honored and will lecture at the Center for Hematology and Blood Transfusion as part of the Center's 75th anniversary celebration.

During his years in Moscow, Dr. Skurkovich was Chief Scientist of the Center's Immunology Laboratory and was responsible for the invention, development and employment of an antistaphylococcal hyperimmune plasma and immunoglobulin for antibiotic-resistant staph infection that saved hundreds of thousands of lives in Russia and Eastern Europe. Dr. Skurkovich was also the pioneer of anti-cytokine therapy during his tenure at the Center.

Commenting on Dr. Skurkovich's visit, Edmond Buccellato, CEO of Advanced Biotherapy, Inc., stated, "We are excited that Dr. Skurkovich will have an opportunity not only to lecture at these distinguished institutes, but will also meet with our collaborative scientists to discuss the company's scientific findings. He will also meet with patients who participated in the company's clinical trials." Mr. Buccellato added, "Dr. Skurkovich will also be meeting with senior scientists at several institutes to discuss the possibility of conducting clinical trials in Russia of the company's developing drug products in other diseases."

The company also announced that Paul J. Marangos, Ph.D., submitted his resignation as a member of the Board of Directors to pursue other business interests and opportunities. Commenting on Dr. Marangos' resignation, Alexander L. Cappello, Chairman of Advanced Biotherapy, Inc. stated, "The company appreciates and recognizes Dr. Marangos' contributions to the advancement of our company over the past year and we wish him continued success in his endeavors."

The Company develops drugs that may effectively treat a range of autoimmune diseases. In two randomized, placebo-controlled, double blind trials conducted in Russia, the Company demonstrated efficacy of its anti-cytokine strategy in both RA and MS. These studies have permitted the Company to determine which cytokines are most active in the autoimmune disease process, and therefore, which need to be removed to most effectively treat these disorders. With a five-day treatment course, statistically significant and clinically relevant responses were obtained that persisted in a one-year follow-up after treatment in the MS studies and a one-month follow-up in the RA studies.

The business strategy of the Company involves the engagement of a corporate partner to assist in the clinical development of its drug treatments for autoimmune disorders. This will involve, upon the identification of such a partner, the filing of the necessary documents with the FDA, conducting clinical trials and obtaining the necessary regulatory approvals, (New Drug Application (NDA) or a 510K device approval). The Company does not intend to market its drug products if they are approved by the FDA, but will instead seek a licensing and royalty arrangement with a corporate partner who will market the product when and if it is approved.

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the company's patent portfolio. See the Company's public filings with the Securities and Exchange Commission for information about risks that may affect the Company.